Vianautis
Patrick Vilela is a highly experienced scientific leader with a robust background in nanomedicine, gene editing, and project management. Currently serving as Senior Principal Scientist - Payloads Lead at Vianautis, Patrick is responsible for designing and leading the onboarding of new payloads, aligning research initiatives with strategic organizational goals, and driving innovation in nanomedicine. Previously, at Evox Therapeutics Ltd, Patrick played a pivotal role as Principal Scientist, overseeing gene editing projects and managing cross-functional teams. With a PhD in Bionanotechnology from the University of Southampton and an MBA from ENEB, Patrick combines scientific expertise with business acumen, contributing to advancements in therapeutic development and pipeline optimization.
This person is not in any teams
Vianautis
ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to exploit the unique capabilities of the revolutionary polyNaut® technology. PolyNaut® is a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This innovative technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials creating ‘a bionic nanoparticle.’ The highly adaptable polymer structure of polyNaut® can be formulated to encapsulate a wide array of genetic cargoes, with sizes exceeding current standards for viral and non-viral delivery. Notably, it enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling. PolyNaut® is set apart from conventional non-viral delivery technologies through its remarkable ability to target specific cells and penetrate biological barriers, including the challenging blood-brain barrier. PolyNaut® nanoparticles, when functionalised for CNS delivery through transcytosis, exhibit exceptional brain uptake. Deploying its state-of-the-art polyNaut® platform, ViaNautis is at the forefront of pioneering new therapies for CNS diseases and cystic fibrosis. The company is actively building an internal pipeline and collaborating with leading pharmaceutical and biotech companies to unlock the potential of promising genetic molecules as well as new therapeutic platforms.